Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.2K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

11.7K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.7K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

1.2K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.2K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

354
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
354

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 induced pluripotent stem cell-derived neural cells.

Disease models & mechanisms·2026
Same author

Promoting Research Excellence in Down Syndrome: Proceedings of the 5th International Conference of the Trisomy 21 Research Society.

Neuromolecular medicine·2026
Same author

Erlotinib and Leflunomide Disrupt 6-Formylindolo[3,2-b]Carbazole Metabolism and Sensitize Keratinocytes to UVA Radiation-Induced Apoptosis.

Photodermatology, photoimmunology & photomedicine·2026
Same author

Ciliogenesis associated kinase 1 accumulates in its inactive form during polycystic kidney disease progression.

bioRxiv : the preprint server for biology·2026
Same author

Mapping the Brain Interaction Network of the Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Targeted by Leucettinib-21 Using Affinity Chromatography.

ACS pharmacology & translational science·2026
Same author

Nitrogen-Doped Graphene Quantum Dots Conjugated to Leucettinib-21 Rescue Differentiating Zebrafish Purkinje Cells by Inhibiting Dyrk1A Kinase.

ACS applied nano materials·2026

相关实验视频

Updated: Sep 9, 2025

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

9.6K

在2型糖尿病的临床前模型中,DYRK1A抑制恢复胰腺功能并改善葡萄糖代谢

Romane Bertrand1, Stefania Tolu1, Delphine Picot1

  • 1Université Paris Cité, BFA, UMR 8251, CNRS, Team « Endocrinology of Diabetes and Fertility », F-75013 Paris, France.

Molecular metabolism
|August 30, 2025
PubMed
概括

在2型糖尿病小鼠模型中,双特异性氨酸调节激酶1A (DYRK1A) 抑制改善了β细胞质量和功能. 这种方法有望恢复葡萄糖平衡并对抗糖尿病.

更多相关视频

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

762
A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
12:33

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

65.5K

相关实验视频

Last Updated: Sep 9, 2025

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

9.6K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

762
A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
12:33

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

65.5K

科学领域:

  • 内分泌学
  • 分子生物学
  • 糖尿病研究

背景情况:

  • 2型糖尿病 (T2D) 的发病包括β细胞功能障碍和损失.
  • 恢复β细胞数量和功能是T2D的关键治疗策略.
  • 双特异性氨酸调节激酶1A (DYRK1A) 调节人类β细胞的增殖,使其抑制剂成为潜在的治疗药物.

研究的目的:

  • 研究慢性DYRK1A抑制对糖尿病缓解的影响.
  • 在临床前T2D模型中评估Leucettinib-92对β细胞质量,功能和葡萄糖代谢的影响.

主要方法:

  • 在体内使用Leucettinib-92治疗糖尿病前和糖尿病后的Goto- Kakizaki (GK) 鼠.
  • 对β细胞增殖,胰岛素分泌,血糖,葡萄糖耐受性和胰岛素敏感性的评估.

主要成果:

  • 在糖尿病前的老鼠中,短期使用Leucettinib-92刺激了β细胞的增殖,并预防了高血糖症.
  • 在糖尿病老鼠中,长期治疗增加了β细胞质量和降低了高血糖.
  • 卢塞蒂尼布-92改善了葡萄糖耐受性和葡萄糖诱导的胰岛素分泌.

结论:

  • 在临床前的T2D模型中,DYRK1A抑制恢复了β细胞质量和功能.
  • 这一策略改善了全球葡萄糖平衡.
  • DYRK1A抑制剂代表了T2D的潜在治疗途径.